<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/46A935BE-E5EE-439F-B71D-F5D5468BE269"><gtr:id>46A935BE-E5EE-439F-B71D-F5D5468BE269</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>Dugald</gtr:otherNames><gtr:surname>Morrison</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800462"><gtr:id>3DCE7543-2C7E-4461-A0EC-7FE6EB1FBD14</gtr:id><gtr:title>Cannabinoids in psychosis: Mechanisms and Therapeutics</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800462</gtr:grantReference><gtr:abstractText>Barely a week goes by without another scare story about cannabis and mental health. This has arisen, partly, because of research findings that forms rich in ?9-tetrahydrocannibinol (THC) can induce psychosis, confer risk for the genesis of schizophrenia, trigger relapse in patients and worsen outcome. 
Schizophrenic illness affects ~1% of the population and onset is typically in early adulthood. It is a frightening disorder, impacting on the highest faculties of the nervous system. Family life, close relationships, education and employment are often devastated and the suicide rate is 100x that of the general population. 
Somewhat ironically, the Cannabis plant (in its natural habitat) contains not just a pro-psychotic agent, ?9-tetrahydrocannibinol (THC) but a highly promising anti-psychotic molecule; cannabidiol (CBD). Pilot work in our laboratory suggests CBD can inhibit THC-psychosis. This is significant because current anti-psychotic medicines do not appear to offer any protection against THC-psychosis. 
In this proposal I aim to demonstrate (statistically) that CBD is effective in blocking THC-psychosis and that, in this regard, it is superior to currently available medicines. This will have important implications, for psychiatric therapeutics and public health and will also expand our knowledge of the effects of these compounds in man. 
A parallel aim is to explore how THC acts in the brain to trigger psychosis. Using EEG recording I will investigate if THC disrupts neural rhythms in the cortex. Such disruption appears to be associated with classic schizophrenic symptoms, especially those in which there is failure to distinguish between self and other. It will be very interesting if THC disrupts neural rhythms in the same fashion.</gtr:abstractText><gtr:technicalSummary>Aims: 
In my previous work I have confirmed that synthetic intravenous (IV) ?9-tetrahydrocannibinol (THC) induces acute psychosis and cognitive deficits in healthy subjects. During the Fellowship I wish to build on these initial findings in two ways. This first aim has therapeutic implications. I intend to build upon pilot data to test the hypothesis that cannabidiol (CBD) will inhibit THC-psychosis. Subsequently, in a formal clinical trial, I will compare the efficacy of CBD versus a currently used antipsychotic medicine (risperidone) in blocking THC-psychopathology. The second aim of this fellowship is to further explore the mechanisms underlying THC-psychosis: Using EEG, I propose to test the hypothesis that THC decreases the consistency of fine-grained neural oscillations which occur ~150ms before a self-generated motor act.
 
Objectives
The first objective is to demonstrate that CBD inhibits THC-psychosis in healthy subjects. As the effect-size appears large, only a small sample (N=~8) is anticipated. This study, (study A), is not covered by the clinical trials directive and the projected timeline is 4 months. The efficacy of CBD v risperidone against THC-psychosis will be compared in a larger study (N=16), conducted under the MHRA directive (Study B) and the projected timeline is 12 months. In the EEG investigation (Study C), protocols developed in the pilot study will be used. Over 12-months I will investigate, in 15 healthy volunteers, the effect of THC on the consistency of neural oscillations, which occur milliseconds before a specific willed act. 
 
Design and Methods
Study A: A controlled, double-blind trial of the efficacy of CBD v placebo in blocking THC-induced psychosis and cognitive impairment. Participants will attend for 2 experimental sessions at least 3 weeks apart. ?Pre-Treatments?, CBD (5mg) or placebo, will be administered intravenously prior to IV THC (1.25mg) as per pilot studies. 
Study B: A controlled, double-blind trial of thficacy of oral CBD v risperidone v placebo in blocking IV THC (1.25mg) induced psychosis and cognitive impairment. To permit comparison, ?pre-treatments? will be administered orally as matched gelatin capsules containing CBD (600mg) or risperidone (3mg). The order of pre-treatments will be randomised.
Study C: A placebo-controlled, double-blind investigation of whether IV THC (1.25mg) decreases the consistency of neural oscillations occurring ~150ms before a particular willed act. Participants (n=15) will attend for 2 experimental sessions and complete blocks of standard motor and vocal tasks. Simultaneous EEG data will be acquired on a Neuroscan Synamps amplifier, electrode caps and Acquire 4.3 software and analysed using Fieldtrip and Neuroscan. 
 
Opportunities: Scientific and medical
To our knowledge this is the first study investigating if THC disrupts the consistency in the EEG signal each time a person prepares a specific act. Similarly, this is the first study to investigate whether CBD inhibits THC-induced psychopathology and the first to investigate atypical antipsychotics in this manner.</gtr:technicalSummary><gtr:fund><gtr:end>2011-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>247468</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Psychiatry</gtr:department><gtr:description>CBD in VR</gtr:description><gtr:id>7088A313-9330-46A2-98B3-1BFE949835C8</gtr:id><gtr:impact>Data collection phase ended Oct 2012.</gtr:impact><gtr:outcomeId>QRRW3uTUcfG-1</gtr:outcomeId><gtr:partnerContribution>Expertise and support in virtual reality paradigms.</gtr:partnerContribution><gtr:piContribution>Design and implementation of the experiments. Data collection.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Psychiatry</gtr:department><gtr:description>THC in VR</gtr:description><gtr:id>6A0F8178-071D-4AAD-BEC7-9979B3EF0C95</gtr:id><gtr:impact>Data collection phase ended in Oct 2012. (n=120)</gtr:impact><gtr:outcomeId>P4GCEESk5MZ-1</gtr:outcomeId><gtr:partnerContribution>Design of psychological aspects. Data collection and analysis.</gtr:partnerContribution><gtr:piContribution>Advice on study design, specifically the pharmacological elements. Hands on support of experimental sessions.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Psychopharmacology Unit</gtr:department><gtr:description>CBD for addiction</gtr:description><gtr:id>31384566-24F6-46E6-A449-C34153495870</gtr:id><gtr:impact>Funding awarded: MRC DCS, 2012</gtr:impact><gtr:outcomeId>H4EVtgMgGQ7-1</gtr:outcomeId><gtr:partnerContribution>Implementation of the research.</gtr:partnerContribution><gtr:piContribution>Research design.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Advisory council - Oral evidence</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>98D1181B-8B3D-491C-A803-D41B082EA929</gtr:id><gtr:impact>Oral presentation of the acute effects of synthetic THC and CBD (components in cannabis) in healthy subjects.

One of the council's recommendations to the government was that the protective effects of CBD should be fully evaluated in humans.</gtr:impact><gtr:outcomeId>2719D90B96D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ACPO - oral evidence</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>D3173E93-44FC-47DF-BFD3-298094B9F067</gtr:id><gtr:impact>Presentation to the Association of Chief Police Officers (England, Wales and Northern Ireland) on the psychopharmacology of cannabinoid molecules.

No subsequent impact</gtr:impact><gtr:outcomeId>D157F3033B6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>All parliamentary group - oral evidence</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>3B229564-010D-410C-A538-000E486153A6</gtr:id><gtr:impact>Presentation on the psychopharmacology of cannabinopid molecules to the Cannabis &amp;amp; Children All Parliamentary Group.

No subsequent impact</gtr:impact><gtr:outcomeId>A8067A4E64E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>140000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industry funded</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>GW Pharmaceuticals</gtr:fundingOrg><gtr:id>509AE301-EFD3-40DD-B71E-3CA5F15303E8</gtr:id><gtr:outcomeId>H6PGQkMUkGb</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99221</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome trust</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>B9E0D055-EFC1-499E-85AF-AA73FD4E29E0</gtr:id><gtr:outcomeId>QR77tJP11bY</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BMA Margaret Temple Award</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>British Medical Association (BMA)</gtr:fundingOrg><gtr:id>EB2E8C9E-4376-4C82-835A-D625C96BD4F3</gtr:id><gtr:outcomeId>jagoUs3tjuB0</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99221</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>R120525</gtr:fundingRef><gtr:id>B3C3ADEE-59D3-49AD-98C0-367981022800</gtr:id><gtr:outcomeId>EXiGE3axX89</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>592629</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Industry funded</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Eli Lilly &amp; Company Ltd</gtr:fundingOrg><gtr:id>2A7ABB41-9382-4919-96A4-9EA84E46CF12</gtr:id><gtr:outcomeId>LAsto3BNcqy</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>376857</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Experimental medicine</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>523B6D90-7610-460C-A26E-2515015D58B6</gtr:id><gtr:outcomeId>rUhP18mg9BX</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Advisory Council on the misuse of drugs</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>57858547-4704-45FB-88EA-BF37001806B4</gtr:id><gtr:impact>Reclassification of cannabis.</gtr:impact><gtr:outcomeId>BXeCrM8HjBR</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>92BB1E61-4B1D-4C5F-A667-808386E7A6F8</gtr:id><gtr:title>Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcdb4d0c0fcb035df8e11215ae279d07"><gtr:id>bcdb4d0c0fcb035df8e11215ae279d07</gtr:id><gtr:otherNames>Bhattacharyya S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>UwCqz3BrgWc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F79BBE97-33AC-42E7-8D6D-FFFA493E3C46</gtr:id><gtr:title>Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light.</gtr:title><gtr:parentPublicationTitle>Frontiers in behavioral neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4dd84d6694736fe9c96593eab5551ac"><gtr:id>e4dd84d6694736fe9c96593eab5551ac</gtr:id><gtr:otherNames>Paparelli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1662-5153</gtr:issn><gtr:outcomeId>pm_13743_23_21267359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05433BEE-84F0-4E03-8EF2-AB317C3CD449</gtr:id><gtr:title>A novel method for reducing the effect of tonic muscle activity on the gamma band of the scalp EEG.</gtr:title><gtr:parentPublicationTitle>Brain topography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d3f32f733e9b3fb91fd66491db03fb0"><gtr:id>3d3f32f733e9b3fb91fd66491db03fb0</gtr:id><gtr:otherNames>Nottage JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0896-0267</gtr:issn><gtr:outcomeId>pm_13743_23_22965826</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5255EA54-9964-4DEF-B358-B429D6CB12BC</gtr:id><gtr:title>Delta-9-tetrahydrocannabinol disruption of time perception and of self-timed actions.</gtr:title><gtr:parentPublicationTitle>Pharmacopsychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b1a2224b337a1dda5d402fdfa5fb51"><gtr:id>49b1a2224b337a1dda5d402fdfa5fb51</gtr:id><gtr:otherNames>Stone JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0176-3679</gtr:issn><gtr:outcomeId>BKjMHqgEPCS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D8C94C7-35EC-4180-B64F-189C131E58DE</gtr:id><gtr:title>Communication breakdown: delta-9 tetrahydrocannabinol effects on pre-speech neural coherence.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49b1a2224b337a1dda5d402fdfa5fb51"><gtr:id>49b1a2224b337a1dda5d402fdfa5fb51</gtr:id><gtr:otherNames>Stone JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>D3R2PhKnsqD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68BFC6F0-DBAA-434C-A36D-2688AF073AF1</gtr:id><gtr:title>The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8518c425eda8de5996a6faf295f0bec"><gtr:id>f8518c425eda8de5996a6faf295f0bec</gtr:id><gtr:otherNames>Morrison PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>40B3D4CADCB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5EBBBA6-6E18-4C24-8E02-37C624E3C737</gtr:id><gtr:title>Does intravenous ?9-tetrahydrocannabinol increase dopamine release? A SPET study.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e2f0f2cd97dc51686a40a631b5d00ef"><gtr:id>9e2f0f2cd97dc51686a40a631b5d00ef</gtr:id><gtr:otherNames>Barkus E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>GUhe72tj6yc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF608FD0-9937-48C5-A145-01C9BA25F251</gtr:id><gtr:title>How cannabis causes paranoia: using the intravenous administration of ?9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7da6b25608d49e1d21662d789ed40543"><gtr:id>7da6b25608d49e1d21662d789ed40543</gtr:id><gtr:otherNames>Freeman D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>5464a17a138a81.78136584</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE166E5C-EBD1-444F-8644-6373B86FF454</gtr:id><gtr:title>Disruption of frontal ? coherence by ?9-tetrahydrocannabinol is associated with positive psychotic symptoms.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8518c425eda8de5996a6faf295f0bec"><gtr:id>f8518c425eda8de5996a6faf295f0bec</gtr:id><gtr:otherNames>Morrison PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>KMMdYB98jWU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>084E091B-9C8E-43D0-93D1-0EF7F221591F</gtr:id><gtr:title>From real-world events to psychosis: the emerging neuropharmacology of delusions.</gtr:title><gtr:parentPublicationTitle>Schizophrenia bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8518c425eda8de5996a6faf295f0bec"><gtr:id>f8518c425eda8de5996a6faf295f0bec</gtr:id><gtr:otherNames>Morrison PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0586-7614</gtr:issn><gtr:outcomeId>BC82EEA35F0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6842DEF-B4F5-4D57-8109-2DA002950679</gtr:id><gtr:title>Cannabis in the arm: what can we learn from intravenous cannabinoid studies?</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5956b5d730eb1a108419277901365e5a"><gtr:id>5956b5d730eb1a108419277901365e5a</gtr:id><gtr:otherNames>Englund A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>pm_13743_23_22716141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>921ED140-113A-4080-A570-C5FB6E43EE97</gtr:id><gtr:title>Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.</gtr:title><gtr:parentPublicationTitle>The American journal of psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31467d4a8a2dee0bc64957171260598f"><gtr:id>31467d4a8a2dee0bc64957171260598f</gtr:id><gtr:otherNames>McGuire P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0002-953X</gtr:issn><gtr:outcomeId>5aa7ebac6e3202.57686808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E64D782-7684-44A5-9DCB-0129A86E7EF4</gtr:id><gtr:title>What can we learn about schizophrenia from studying the human model, drug-induced psychosis?</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3aa1a9a5f22dc4f696a5505a4e6ea5d4"><gtr:id>3aa1a9a5f22dc4f696a5505a4e6ea5d4</gtr:id><gtr:otherNames>Murray RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1552-4841</gtr:issn><gtr:outcomeId>pm_13743_23_24132898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41308463-A1A0-4F8B-B2F5-0AD2CBE929F5</gtr:id><gtr:title>Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation.</gtr:title><gtr:parentPublicationTitle>Human psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8518c425eda8de5996a6faf295f0bec"><gtr:id>f8518c425eda8de5996a6faf295f0bec</gtr:id><gtr:otherNames>Morrison PD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0885-6222</gtr:issn><gtr:outcomeId>jiB4y4qheMK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FB0DFD1-D75B-4F64-A1B5-71EF4D4EBEFC</gtr:id><gtr:title>Advancing the defensive explanation for anxiety disorders: lorazepam effects on human defense are systematically modulated by personality and threat-type.</gtr:title><gtr:parentPublicationTitle>Translational psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c60a0f28e93b99cb8d9546cf82728ff"><gtr:id>8c60a0f28e93b99cb8d9546cf82728ff</gtr:id><gtr:otherNames>Perkins AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2158-3188</gtr:issn><gtr:outcomeId>pm_13743_23_23591970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A553340-C101-428F-AA4D-468603C15E20</gtr:id><gtr:title>The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9eac30bc93b190ded9e411fea6f15518"><gtr:id>9eac30bc93b190ded9e411fea6f15518</gtr:id><gtr:otherNames>Hundal H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>5aa7ebac9eecd5.48586457</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D09524D3-A42B-4E9A-902A-3F0601FE7970</gtr:id><gtr:title>Delta-9-tetrahydrocannabinol, neural oscillations above 20&amp;nbsp;Hz and induced acute psychosis.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d3f32f733e9b3fb91fd66491db03fb0"><gtr:id>3d3f32f733e9b3fb91fd66491db03fb0</gtr:id><gtr:otherNames>Nottage JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>5464a07fb4e565.06387374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13125BB9-F0A7-4876-BAD7-AD3A6AC84F55</gtr:id><gtr:title>The effect of cannabis on perception of time: a critical review.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abd3c1204c86db4367cf308ab6266faf"><gtr:id>abd3c1204c86db4367cf308ab6266faf</gtr:id><gtr:otherNames>Atakan Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>pm_13743_23_22716134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>139B652C-8672-40A4-BA80-F913BE91F5A0</gtr:id><gtr:title>Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5956b5d730eb1a108419277901365e5a"><gtr:id>5956b5d730eb1a108419277901365e5a</gtr:id><gtr:otherNames>Englund A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>pm_13743_23_23042808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>273E7D4B-33B3-43A8-8E52-474DF6D9E9E9</gtr:id><gtr:title>Persecutory ideation and a history of cannabis use.</gtr:title><gtr:parentPublicationTitle>Schizophrenia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7da6b25608d49e1d21662d789ed40543"><gtr:id>7da6b25608d49e1d21662d789ed40543</gtr:id><gtr:otherNames>Freeman D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0920-9964</gtr:issn><gtr:outcomeId>pm_13743_23_23806582</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800462</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>13981021-24EA-4648-A954-C235506E2CD9</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>3.2  Interventions to alter physical and biological environmental risks</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>